Does atorvastatin 20 mg reduce heart attack/stroke risk long term?

This is a follow-up question about atorvastatin 20 mg, but it is a different question: not "does it lower LDL" but "does it reduce heart attack and stroke risk long term." The retrieved records do not answer that question. They are about ventricular arrhythmias after a heart attack [1], LDL goal attainment [2], and perioperative statins [3]. None of them is a long-term trial of atorvastatin 20 mg against placebo with hard clinical endpoints like heart attack, stroke, or death. The one head-to-head trial [1] is an 8-week surrogate-marker study in 76 patients, not a long-term outcome trial. The 2024 meta-analysis [3] covers cardiac surgery patients and found no reduction in 30-day death or complications, which is a different population and a different time horizon.

So the honest answer is: the evidence retrieved does not establish that atorvastatin 20 mg reduces heart attacks or strokes long term. It establishes that the drug lowers LDL and apolipoprotein B in the short term [1][2]. Whether that translates into fewer hard events is a question the retrieved records do not touch. The 2013 study [1] is non-randomized, so even its short-term findings are confounded. The 2024 meta-analysis [3] is randomized but in a narrow surgical population and found no mortality benefit. There is no long-term placebo-controlled trial here, no all-cause mortality data, no stroke data specific to this dose.

My confidence that atorvastatin 20 mg reduces long-term heart attack and stroke risk: low, because the evidence is absent, not because it contradicts the claim. The burden of proof is on the intervention. The retrieved records do not meet it.